Abstract With the introduction in the clinical practice of drugs inhibiting vascular endothelial growth factor (VEGF) the visual outcomes of patients with neovascular age related macular degeneration (AMD) dramatically improved. Since 2006 repeated intravitreal injections of anti-VEGF became the standard of care for the treatment of neovascular AMD. This review provides an overview of available data form clinical trials supporting the use of anti-VEGF molecules for the treatment of this condition. Several questions remain open, in particular the regimen of treatment, the frequency of injection, the safety of the different drugs, and the poor response to the treatment in some cases. Therefore, new agents and alternative delivery are currently under evaluation.

Treatment for neovascular age related macular degeneration: The state of the art

EANDI, Chiara Maria
Last
;
ALOVISI, CAMILLA;DE SANCTIS, Ugo;GRIGNOLO, Federico
2016-01-01

Abstract

Abstract With the introduction in the clinical practice of drugs inhibiting vascular endothelial growth factor (VEGF) the visual outcomes of patients with neovascular age related macular degeneration (AMD) dramatically improved. Since 2006 repeated intravitreal injections of anti-VEGF became the standard of care for the treatment of neovascular AMD. This review provides an overview of available data form clinical trials supporting the use of anti-VEGF molecules for the treatment of this condition. Several questions remain open, in particular the regimen of treatment, the frequency of injection, the safety of the different drugs, and the poor response to the treatment in some cases. Therefore, new agents and alternative delivery are currently under evaluation.
1
6
www.elsevier.com/locate/ejphar
Angiogenesis; Anti-VEGF; Choroid; Degeneration; Macula; Retina; Pharmacology
Eandi, Chiara M; Alovisi, Camilla; De Sanctis, Ugo; Grignolo, Federico.
File in questo prodotto:
File Dimensione Formato  
Treatment for neovascular age related macular degeneration.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 330.96 kB
Formato Adobe PDF
330.96 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
1-s2.0-S0014299916301133-main.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 292.12 kB
Formato Adobe PDF
292.12 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1564931
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 19
social impact